Abstract
CALQUENCE (Acalabrutinib) is a kinase inhibitor. The chemical name is 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide (2Z)-2-butenedioic acid hydrate. The active pharmaceutical ingredient (API) is in the form of the maleate salt monohydrate in CALQUENCE® tablets, a prescription medication for use in the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Anonymous, "METHOD OF PREPARING CRYSTALLINE FORM ACALABRUTINIB MALEATE MONOHYDRATE", Technical Disclosure Commons, ()
https://www.tdcommons.org/dpubs_series/9449